2月10日，三大指数涨跌不一，创新药板块表现强势。截至当日收盘，恒生沪深港创新药精选50指数 (HSSSHID.HK)上涨2.26%收获六连阳，该指数成分股中，信立泰上涨近7%，石药集团与荣昌生物 （A）上涨超5%，信达生物上涨近5%。 海通国际证券指出，港股医药板块经历前期连续调整后，市场情绪有所回暖。随着港股业绩期临近，我 们看好业绩确定性强的互联网医疗、CXO/科研服务龙头。此外，我们建议持续关注本轮调整中回调幅 度较大的优质创新药龙头企业。 相关ETF方面，wind金融终端显示，截至当日收盘，创新药ETF天弘（517380）成交额超3700万元。资 金流向方面，截至2月9日，该ETF已连续3个交易日获资金净流入，累计净流入额为4166.12万元。该 ETF最新流通份额为25.04亿份，最新流通规模为19.63亿元。此外，生物医药ETF（159859）当日成交 额超1亿元，居同标的产品第一。该ETF最新流通份额为95.96亿份，最新流通规模为37.96亿元。 （文章来源：21世纪经济报道） 创新药ETF天弘（517380）为全市场唯一一只跟踪恒生沪港深创新药精选50指数的ETF，汇聚中国硬核 创新药力量 ...

Group 1 - The three major indices experienced fluctuations and turned negative, with the pharmaceutical and biotechnology sectors declining. The medical device sector saw a slight drop, with the CSI Medical Devices and Services Index falling by 0.34%. Notable gainers included Yingke Medical, which rose over 3%, and Hualan Shares and Guanhao Biological, which also had significant increases [1] - The Medical Device ETF (159873) recorded a half-day trading volume of nearly 9 million yuan, leading among similar products, with a turnover rate exceeding 3%. Over the past 10 days, the ETF has seen a cumulative net inflow of 119 million yuan, bringing its latest scale to 236 million yuan, making it the largest in its category [1] - The Medical Device ETF closely tracks the CSI Medical Devices and Services Index, which selects listed companies corresponding to the healthcare theme from the CSI All Share Index to reflect the overall performance of these companies [1] Group 2 - The Innovation Drug ETF Tianhong (517380) has also seen continuous net inflows, accumulating 426 million yuan over the past 12 days. It is the only ETF in the market tracking the Hang Seng Hong Kong-Shenzhen Innovation Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization [2] - According to industry insiders, multiple public fund institutions have applied for medical and healthcare-themed funds this year. It is anticipated that the pharmaceutical industry will gradually recover from its bottom by 2026, with overall revenue growth stabilizing. Key focus areas will include the innovative drug industry chain, CXO (Contract Research Organization) sector, and innovative medical consumables [2] - CITIC Securities highlighted the significance of innovation, noting that Chinese pharmaceuticals possess advantages in "innovation upgrades and supply chain resilience." By 2025, the upfront payments for overseas licensing of innovative drugs are expected to significantly exceed the total for the previous year, with medical devices also exploring international markets [2]

消息面上，据媒体消息，第44届摩根大通医疗健康大会（JPM2026）于1月12日至15日在美国旧金山召 开，此次会议聚焦生物技术、生物制药、AI+医药等六大领域。作为全球生物医药行业的"春晚"，每年 1月举办的JPM大会是全球医药行业最重要的投资与交易窗口之一，可一睹全球医药生物产业发展的最 新动态。 中泰证券认为，多重因素推动下，医药板块中CRO、CDMO需求端呈逐步恢复态势，叠加过去三年供 给端持续出清，板块有望迎来盈利与估值同时提升的"戴维斯双击"。 中信建投证券表示，中国医药产业已迈入"创新兑现+全球布局"的关键阶段，人口与内需基数、全产业 链制造能力构成核心支撑，企业积极探索多元化的出海路径。展望2026年，可以重点关注创新商业化、 全球化突破、政策优化带来的新增量及行业并购整合的机遇。 （文章来源：21世纪经济报道） 1月16日，市场早盘高开回落，三大指数集体翻绿。 相关ETF方面，创新药ETF天弘（517380）截至午间收盘成交额超2200万元。 资金流向方面，截至1月15日，该ETF近10个交易日累计净流入额近3亿元。 创新药ETF天弘（517380）为全市场唯一一只跟踪恒生沪港深创新药精选5 ...

Group 1 - The core viewpoint is that the integration of AI in healthcare and pharmaceuticals is gaining momentum, with significant stock price increases in related companies such as Meinian Health and Zhaoyan New Drug [1] - The Medical Equipment ETF (159873) has seen continuous capital inflow over the past four days, totaling 26.5 million yuan, reaching new highs in both scale and shares since its inception [2] - The Medical Equipment ETF has a high concentration in brain-computer interface technology, accounting for over 17%, with nearly 80% of its components from the Sci-Tech Innovation Board and the Growth Enterprise Market, indicating strong technological attributes [2] Group 2 - The Innovative Drug ETF Tianhong (517380) has experienced net inflows for six consecutive days, with a total of 254 million yuan in the last five days, reflecting strong investor interest [3] - The Innovative Drug ETF spans the Shanghai, Hong Kong, and Shenzhen markets, covering the entire industry chain from preclinical research to commercialization, which helps mitigate investment uncertainties [3] - OpenAI's launch of ChatGPTHealth marks the beginning of an AI-driven healthcare era, enhancing privacy through data isolation and involving over 260 doctors from 60 countries in model optimization [3]

Group 1 - The three major indices experienced fluctuations and upward movement, with the pharmaceutical and biotechnology sector showing significant gains, particularly the medical device sector which rose by 1.14% [1] - Notable stocks included Tianzhihang-U, which surged over 15%, and Yingke Medical, which increased by more than 10%, along with several stocks reaching their daily limit [1] - The Medical Device ETF (159873) saw a substantial increase in trading volume, with over 26 million yuan in transactions and a turnover rate of 17%, marking it as the largest among its peers [1] Group 2 - The Medical Device ETF (159873) has recorded a net inflow of 26.5 million yuan over four consecutive days, leading its category with a net inflow rate exceeding 22% [1] - The ETF tracks the CSI All-Share Healthcare Equipment and Services Index, which has a significant focus on brain-computer interface concepts, accounting for over 19% of its composition [1] - The latest scale of the Medical Device ETF (159873) reached 152 million yuan, making it the largest in its category [1] Group 3 - The Tianhong Innovative Drug ETF (517380) is the only ETF in the market tracking the Hang Seng Hong Kong-Shenzhen Innovative Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization [2] - Recent developments include a partnership between NVIDIA and Eli Lilly, where they plan to invest 1 billion USD over five years to establish a joint research lab in the San Francisco Bay Area, aimed at accelerating AI applications in the pharmaceutical industry [2] - The AI+Healthcare market is projected to exceed 100 billion USD, with significant advantages over traditional pharmaceutical research, creating a competitive edge through a closed-loop system of algorithms, data, and clinical scenarios [2]

Group 1 - The A-share and Hong Kong stock markets showed strength on January 12, with the innovative drug concept experiencing fluctuations after several days of rebound; the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index fell by 0.63% at the time of reporting, while stocks like CSPC Pharmaceutical Group, BeiGene, and Boteng Co., Ltd. saw slight increases [1] - Since the beginning of 2026, as of the close on January 9, the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index has rebounded over 10% cumulatively [1] - The Tianhong Innovative Drug ETF (517380) was actively traded, with a transaction amount exceeding 40 million yuan and a premium rate of 0.78% at the time of reporting; it has seen continuous capital inflow, accumulating over 170 million yuan from January 7 to 9 [1] Group 2 - According to Zhongtai Securities, it is recommended to focus on three dimensions for investment in 2026: "innovative drugs and their industrial chain, demand recovery and operational turning points, and AI+" [2] - Continuous attention should be paid to the AI+ theme, the positive catalysts from the JPM conference in the innovative drug sector, and the potential for exceeding annual performance forecasts or clearing turning point opportunities [2]

Group 1 - The pharmaceutical sector showed weakness on December 30, with the Hang Seng Hong Kong-Shanghai Innovation Drug Select 50 Index down by 0.56% [1] - Among the constituent stocks, Gan Li Pharmaceutical, Hao Yuan Pharmaceutical, and Junshi Biosciences saw the highest gains, while Baijia Shenzhou, WuXi AppTec, and Kailai Ying experienced declines [1] - The Tianhong Innovation Drug ETF (517380), which tracks the Hang Seng Hong Kong-Shanghai Innovation Drug Select 50 Index, has a total fund size of 1.381 billion yuan and has seen a share increase of over 308% year-to-date, with the latest share count at 1.848 billion [1] Group 2 - Huadong Medicine announced that its subsidiary received a notice from the Ministry of Agriculture and Rural Affairs regarding the acceptance of a new veterinary drug registration application for HDM7006, aimed at weight management in adult obese cats [1] - Xinda Securities believes that the spring market is about to start, recommending attention to emerging pharmaceutical industries such as brain-computer interfaces, surgical robots, and AI applications, with a long-term focus on innovation and international expansion in the medical investment sector [1] - Huaxi Securities points out that the innovation drug industry chain will be the main line of the pharmaceutical sector by 2026, highlighting two key trends: marginal improvement in overseas demand and reversal of domestic demand challenges [2]

Group 1 - The three major indices opened lower on December 9, with the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Selected 50 Index (HSSSHID.HK) rising over 1%, driven by significant gains in stocks like Zhaoyan New Drug and WuXi AppTec, which both increased by over 10% [1] - The Tianhong Innovative Drug ETF (517380) showed strength with a real-time premium rate of 0.17%, and it recorded a net inflow of 15.58 million yuan on the previous trading day, marking eight consecutive days of net inflows totaling 113 million yuan [1] - The new National Medical Insurance Drug List, effective from January 1, 2026, adds 114 new drugs, including 50 Class 1 innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives, increasing the total number of drugs in the list to 3,253 [1] Group 2 - The Tianhong Innovative Drug ETF tracks the Hang Seng Hong Kong-Shenzhen Innovative Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization, allowing for investment in both A-share and Hong Kong stocks in innovative drugs and CXO leading enterprises [2] - CITIC Securities believes that the success rate of national medical insurance negotiations is at a record high, and the commercial insurance directory is expected to become an important growth driver, with policies encouraging the development of innovative drugs [2] - The international competitiveness of China's innovative drug pipeline continues to improve, with ongoing upgrades in overseas expansion models and new technologies driving rapid industry development [2]

Group 1 - The Hang Seng Shanghai Shenzhen Hong Kong Innovation Drug Selected 50 Index (HSSSHID.HK) decreased by 0.38% on October 22, with Rongchang Biologics and Huyou Pharmaceutical rising over 2% [1] - The National Biomedicine Index (399441.SZ) fell by 0.11%, with Rongchang Biologics again showing a rise of over 2% [1] - The Tianhong Innovation Drug ETF (517380) dropped by 0.74%, with a trading volume of 13.43 million yuan and a real-time premium rate of 0.02% as of October 21 [1] Group 2 - Innovent Biologics announced a global strategic partnership with Takeda Pharmaceutical to advance the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, with an upfront payment of $1.2 billion and potential milestone payments totaling up to $10.2 billion, making the total deal value up to $11.4 billion [2] - The National Medical Products Administration (NMPA) is enhancing the legal standard system and increasing support for R&D innovation to accelerate the market entry of innovative medical devices [2] - Beijing's medical instrument and device exports reached 5.83 billion yuan in the first eight months of the year, reflecting a year-on-year growth of 21.5% [2] Group 3 - The Tianhong Innovation Drug ETF (517380) is the largest in the market, tracking the Hang Seng Shanghai Shenzhen Hong Kong Innovation Drug Selected 50 Index, covering both A-shares and Hong Kong stocks [3] - The National Biomedicine Index includes the top 30 stocks based on market capitalization and liquidity from the A-share market, reflecting the overall performance of the biomedicine industry [3] - Huafu Securities believes that China's innovative drugs are experiencing a "qualitative change driven by quantitative change," and suggests focusing on companies with both business development (BD) expectations and commercial sales support [3]

Group 1 - The innovation drug concept continues its rebound, with the Tianhong Innovation Drug ETF (517380) rising by 2.35% and component stocks like Sanofi Pharmaceutical increasing over 8% [1] - The Biopharmaceutical ETF (159859) has risen by 1.17%, with a trading volume nearing 50 million yuan, leading among similar products [1] - On October 13, CSPC Pharmaceutical Group (1093.HK) announced that its subsidiary's new drug application for Idaglutide α injection has been accepted, aimed at long-term weight management for overweight or obese adults [1] Group 2 - The Biopharmaceutical ETF (159859) closely tracks the Biopharmaceutical Index, which includes the top 30 stocks in the A-share market based on market capitalization and liquidity, reflecting the overall performance of the biopharmaceutical industry [2] - Huafu Securities believes that China's innovative drugs are experiencing a "quantitative change leading to qualitative change," with a positive outlook on the industry trend over the next 5 to 10 years driven by business development (BD) overseas, continuous data catalysts, and new product sales [2] - Guotai Haitong emphasizes that the current market is trading on the logic of innovative drug overseas expansion, with BD transactions becoming a key valuation basis, and leading innovative drug companies with high R&D efficiency and strong overseas collaboration are expected to benefit first [2]